Clinical Trial

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

Name: A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder — clinical trial record (NCT07219966)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RENEW-ALC-1

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.

Trial Details

NCT Number	NCT07219966
Lead Sponsor	Eli Lilly and Company
Conditions	Alcohol Use Disorder
Enrollment	1,100 participants
Start Date	2025-10-15
Primary Completion	2028-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-07